Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, et al

Heavy or Dependent Drinking If alcohol consumption exceeds 14+ drinks per week, or if stopping creates withdrawal symptoms: Medical supervision is essential: Combining retatrutide with heavy alcohol use requires close monitoring Address alcohol use first: Consider addiction medicine consultation before optimizing weight loss medication GLP-1 agonists may reduce alcohol cravings: Emerging research suggests these medications decrease alcohol seeking behavior in some people Liver damage risk is significant: The combination creates substantial hepatotoxic potential Consider treatment programs: Resources like CAMH (Centre for Addiction and Mental Health) offer evidence-based approaches Interestingly, some research suggests GLP-1 receptor agonists may actually help reduce alcohol consumption in people with alcohol use disorder, though this remains an area of active investigation rather than established clinical practice

Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes Huang Y, He Y, Makarcyzk MJ, Lin H Frontiers in Bioengineering and Biotechnology (2021) This study demonstrated that FOXO4-DRI selectively removes senescent cells from human chondrocyte cultures expanded in vitro, providing direct evidence of the peptide's senolytic activity in human cells relevant to joint and cartilage aging
The health and safety hazards associated with the handling of peptides in a research setting
What is Exenatide extended release (Bydureon BCise)
15-20 minute monthly appointments None